person

David P Walling, PhD

David WallingDavid Walling, MDDavid Walling, PhD

ORCID 0000-0001-8638-2086

as of 2026-07-01

Monitor this Ask about this

at a glance

Roles: Principal Investigator, Author

KOL signal score 17

5 publications · 2 high-value

Cross-drug reach: 3 competitor drugs

Synthesized from structured facts only — each point cited above.

Profile

Affiliation

Collaborative Neuroscience Network

Roles

Principal Investigator, Author

KOL signal

Publications

5 (2 high-value)

Trial investigator

yes

Publishes on

3 drugs

Amisulpride Emraclidine Xanomeline-trospium (Cobenfy)

Trials led

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

NCT02724917Phase 1, Phase 2Suspended

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCT04822883Phase 2Completed

Study of SPG302 in Adults With Schizophrenia

NCT06442462Phase 2Active Not Recruiting

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCT01488929Phase 2Completed

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

NCT03978832Phase 4Completed

Bio-equivalence Study Between SAPHRIS and Asenapine

NCT01948024Phase 1Completed

Publications & congress

Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.

JAMA psychiatry · 2024 · high-value

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.

Lancet (London, England) · 2022 · high-value

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.

JAMA psychiatry · 2026

Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.

Schizophrenia (Heidelberg, Germany) · 2025

Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.

Schizophrenia (Heidelberg, Germany) · 2024